The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor

(Length of Conversation: 11 minutes)

Charles Ryan, MD and Oliver Sartor, MD cover three interesting topics in prostate cancer from the 2018 ASCO Annual Meeting. Oliver provides his view on potential clinical implications relative to the ERA 223 phase 3 trial with Radium-223.  Discussion ensues on novel nuclear medicine approaches to treating prostate cancer including Lutetium 177 PSMA and Actinium PSMA-225. Lastly, a concise review of a recent education session on DNA repair in Prostate Cancer, including both germ-line and somatic testing.

Biographies:
Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research

Charles J. Ryan, MD

Related Content:

Joining Forces to Address Unanswered Questions - The European PEACE Consortium - Interview with Karim Fizazi

PROPHECY - A Prospective Trial of Circulating Tumor Cell AR-V7 Detection in mCRPC with Abiraterone or Enzalutamide